Wajiski's original vision was to turn genetics from the rarefied work of hiand labs into mainstream health and quasi entertainment products. She'd sell taste makers on her malin spit kits as a way to learn sort of interesting things about their d and a make-up. 23 and me would become a new kind of health care business, sitting somewhere between a big farmal b a big tech company and a trusted neighborhood doctor. Some of this still sounds as far off now as it did during the bush years,. improbably, though 23 and me has rounded second base and is heading for third.
This week's Cover Story for Bloomberg Businessweek:
'23andMe Wants to Use Its Customers’ Genetic Data to Beat Cancer'
Read by Bloomberg's Mark Leydorf
CEO Anne Wojcicki wants to make drugs using insights from millions of customer DNA samples, and doesn’t think that should bother anyone.
See omnystudio.com/listener for privacy information.